

UNITED STATES DEPARTMENT OF COMMERCE

Pat nt and Trademark Offic

Addr ss: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

FILING DATE APPLICATION NO. FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 09/316,199 05/21/99 MCCLUSKIE

М C1040/7006HC

HM22/1205

EXAMINER

HELEN C LOCKHART WOLF GREENFIELD & SACKS PC 600 ATLANTIC AVENUE BOSTON MA 02210

STROUP, C **ART UNIT** PAPER NUMBER 1633

DATE MAILED:

12/05/00

Pleas find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

| SERIAL NUMBER | FILING DATE | | FIRST NAMED APPLICANT | ATTORNEY DOCKET NO. |
|---------------|-------------|-----------------|-----------------------|---------------------|
| 09/316,199 | 5/21/99 | McCluskie et al | <u> </u> | C1040/7006HC |

| EXAMINER | | | | |
|---------------|--------------|--|--|--|
| Carrie Stroup | | | | |
| ART UNIT | PAPER NUMBER | | | |
| 1633 | 8 | | | |

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner Carrie Stroup, Art Unit 1633, whose telephone number is (703) 306-5439.

Any inquiry of a general nature or relating to the status of this application sould be directed to the Technology Center receptionist whose telephone number is (703)308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Application No.:09/316,199 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

| | This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. |
|-----|---|
| | 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). |
| | 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). |
| X | 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." |
| | 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). |
| | 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). |
| | 7. Other: |
| Ap | plicant Must Provide: |
| X | An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". |
| X | An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. |
| X | A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). |
| For | questions regarding compliance to these requirements, please contact: |
| For | Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support (SIRA) Technical Assistance |
| | To Purchase Patentin Software 703-306-2600 |

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

SERIAL NUMBER: ERROR DETECTED SUGGESTED CORRECTION ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE The number/text at the end of each line "wrapped" down to the n xt line. 1 ____ Wrapped Nucleics This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping". The amino acid number/text at the end of each line "wrapped" down to the next line. 2 Wrapped Aminos This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping". The rules require that a line not exceed 72 characters in length. This includes spaces. incorrect Line Length The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs ___ Misaligned Amino Acid between the numbering. It is recommended to delete any tabs and use spacing between the numbers. Numbering This file was not saved in ASCII (DOS) text, as required by the Sequence Rules. __ Non-ASCII Please ensure your subsequent submission is saved in ASCII text so that it can be processed. Sequence(s) ____ contain n's or Xaa's which represented more than one residue. 6 ____ Variable Length As per the rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing. A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid 7 ____ Patentin ver. 2.0 "bug" . Normally, Patentin would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. Sequence(s) ____ missing. If intentional, please use the following format for each skipped sequence: 8 _____ Skipped Sequences (OLD RULES) (2) INFORMATION FOR SEQ ID NO:X: (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS") (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: This sequence is intentionally skipped Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s). Sequence(s) ____ missing. If intentional, please use the following format for each skipped sequence. Skipped Sequences (NEW RULES) <210> sequence id number <400> sequence id number 000 10 ____ Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing. (NEW RULES) Use of <220> to <223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents. Sequence(s) _____ are missing this mandatory field or its response. Use of <213>Organism 1-34 (maybe mere)
____ are missing the <220>Feature and associated headings. Use of <220>Feature Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown" (NEW RULES) Please explain source of genetic material in <220> to <223> section.

Patentin ver. 2.0 "bug"

Please do not use "Copy to Disk" function of Patentin version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).

Instead, please use "File Manager" or any other means to copy file to floppy disk.

(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32)

(Sec. 1.823 of new Rules)

AKS-Biotechnology Systems Branch- 5/15/99